Providing leading genomic services & solutions

NovoFocus™ NSCLC CDx Liquid Biopsy Test

Service Overview
Novogene Data
Contact Us

NovoFocus-NSCLC-Liquid-BiopsyLiquid biopsy is a simple and minimally invasive technology that enable testing molecular biomarkers of cancer from a simple blood draw, which may benefit patients who are unable to undergo a surgical biopsy. In spite of several approved PCR-based mutation tests in circulating-tumor DNA (ctDNA) for NCSLC targeted therapies, the next-generation sequencing (NGS), owning to its broad coverage and high sensitivity, has developed rapidly during the last decade and is expected to be widely applied in detection of the targeted biomarkers of cancer.

NovoFocus™ NSCLC CDx Liquid Biopsy Test is an NGS-based companion diagnostic test used as a companion to targeted therapeutic drugs for NSCLC patients. This panel covers all the gene targets as well as its related therapies recommended by NCCN Guidelines (2019v2) for NSCLC, aiming to provide patients with comprehensive guidance for the drug treatments.

NovoFocus™ NSCLC CDx Liquid Biopsy Test Gene List
8 Gene targets for therapeutic use recommended by NCCN Guidelines or approved by FDA.
EGFR Afatinib, Erlotinib, Gefitinib, Dacomitinib, Osimertinib
ALK Alectinib, Ceritinib, Crizotinib, Brigatinib, Lorlatinib
ROS1 Ceritinib, Crizotinib
BRAF Dabrafenib/Trametinib
MET Crizotinib
RET Cabozantinib,Vandetanib
HER2 Ado-trastuzumab emtansine
NTRK1 Larotrectinib
8 additional gene targets included in this test
PIK3CA AKT1 KRAS
NRAS KIT PDGFRA
TP53 UGT1A1

Sequencing Strategy

  • NovaSeq 6000, PE150

Sequencing Coverage

  • All coding exons and ± 20bp intron regions

Sample Requirements

  • 50ng

Turnaround Time

  • 10 calendar days from sample receipt to report delivery

For Research Use Only. The content provided herein may relate to products that have not been approved for clinical use by the regulatory authorities of where this document is circulated. The application of such products should thus be limited to research only. The content of this document is subject to change without notice. © 2018 Novogene Co., LTD. All rights reserved. All trademarks are the property of Novogene Co., LTD and its subsidiaries unless otherwise specified.